Voluntary disclosure of the announcement regarding the approval of the indications for the use of empagliflozin and metformin hydrochloride in the treatment of type 2 diabetes.

SZSI · Jul 20

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.